
Investors Face August Deadline in ADMA Biologics Securities Lawsuit
Investors who purchased ADMA Biologics, Inc. securities between August 9, 2024, and March 25, 2026, face an August 10, 2026, deadline to seek appointment as lead plaintiff in a class action lawsuit alleging the company misled shareholders through undisclosed related-party transactions and revenue inflation.





















.png)






